These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

281 related articles for article (PubMed ID: 23452742)

  • 21. Laboratory diagnosis and molecular classification of von Willebrand disease.
    Gadisseur A; Hermans C; Berneman Z; Schroyens W; Deckmyn H; Michiels JJ
    Acta Haematol; 2009; 121(2-3):71-84. PubMed ID: 19506352
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Dominant von Willebrand disease type 2M and 2U are variable expressions of one distinct disease entity caused by loss-of-function mutations in the A1 domain of the von Willebrand factor gene.
    Gadisseur A; van der Planken M; Schroyens W; Berneman Z; Michiels JJ
    Acta Haematol; 2009; 121(2-3):145-53. PubMed ID: 19506361
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Von Willebrand's disease in the year 2003: towards the complete identification of gene defects for correct diagnosis and treatment.
    Castaman G; Federici AB; Rodeghiero F; Mannucci PM
    Haematologica; 2003 Jan; 88(1):94-108. PubMed ID: 12551832
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Laboratory response to intranasal desmopressin in women with menorrhagia and platelet dysfunction.
    Rose SS; Faiz A; Miller CH; Saidi P; Philipp CS
    Haemophilia; 2008 May; 14(3):571-8. PubMed ID: 18312366
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Von Willebrand disease and other bleeding disorders in women: consensus on diagnosis and management from an international expert panel.
    James AH; Kouides PA; Abdul-Kadir R; Edlund M; Federici AB; Halimeh S; Kamphuisen PW; Konkle BA; Martínez-Perez O; McLintock C; Peyvandi F; Winikoff R
    Am J Obstet Gynecol; 2009 Jul; 201(1):12.e1-8. PubMed ID: 19481722
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Laboratory monitoring of therapy in von Willebrand disease: efficacy of the PFA-100 and von Willebrand factor:collagen-binding activity as coupled strategies.
    Favaloro EJ
    Semin Thromb Hemost; 2006 Sep; 32(6):566-76. PubMed ID: 16977567
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Diagnosis and management of von Willebrand disease: a developing country perspective.
    Nair SC; Viswabandya A; Srivastava A
    Semin Thromb Hemost; 2011 Jul; 37(5):587-94. PubMed ID: 22102204
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Guidelines for the diagnosis and management of von Willebrand disease in Italy.
    Federici AB; Castaman G; Mannucci PM;
    Haemophilia; 2002 Sep; 8(5):607-21. PubMed ID: 12199668
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Laboratory diagnosis and monitoring of desmopressin treatment of von Willebrand's disease by flow cytometry.
    Giannini S; Mezzasoma AM; Leone M; Gresele P
    Haematologica; 2007 Dec; 92(12):1647-54. PubMed ID: 18055988
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Review article: unexpected bleeding in the operating room: the role of acquired von Willebrand disease.
    Lison S; Dietrich W; Spannagl M
    Anesth Analg; 2012 Jan; 114(1):73-81. PubMed ID: 22025497
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Comprehensive evaluation of haemostatic function in von Willebrand disease patients using a microchip-based flow chamber system.
    Ogiwara K; Nogami K; Hosokawa K; Ohnishi T; Matsumoto T; Shima M
    Haemophilia; 2015 Jan; 21(1):71-80. PubMed ID: 25545301
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Diagnosis and management of von Willebrand disease].
    Higasa S; Tokugawa T; Sawada A
    Rinsho Ketsueki; 2018; 59(10):2222-2232. PubMed ID: 30305529
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Management of inherited von Willebrand disease in 2006.
    Federici AB
    Semin Thromb Hemost; 2006 Sep; 32(6):616-20. PubMed ID: 16977571
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Haemostatic management of intraoral bleeding in patients with von Willebrand disease.
    Morimoto Y; Yoshioka A; Sugimoto M; Imai Y; Kirita T
    Oral Dis; 2005 Jul; 11(4):243-8. PubMed ID: 15984956
    [TBL] [Abstract][Full Text] [Related]  

  • 35. PFA-100 monitoring of von Willebrand factor (VWF) responses to desmopressin (DDAVP) and factor VIII/VWF concentrate substitution in von Willebrand disease type 1 and 2.
    van Vliet HH; Kappers-Klunne MC; Leebeek FW; Michiels JJ
    Thromb Haemost; 2008 Sep; 100(3):462-8. PubMed ID: 18766263
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Recessive von Willebrand disease type 2 Normandy: variable expression of mild hemophilia and VWD type 1.
    Michiels JJ; Gadisseur A; Vangenegten I; Schroyens W; Berneman Z
    Acta Haematol; 2009; 121(2-3):119-27. PubMed ID: 19506358
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Acquired von Willebrand disease.
    Kumar S; Pruthi RK; Nichols WL
    Mayo Clin Proc; 2002 Feb; 77(2):181-7. PubMed ID: 11838652
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Prophylaxis in von Willebrand disease.
    Franchini M; Targher G; Lippi G
    Ann Hematol; 2007 Oct; 86(10):699-704. PubMed ID: 17634944
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Diagnosis and therapeutic management in a patient with type 2B-like acquired von Willebrand syndrome.
    Karger R; Weippert-Kretschmer M; Budde U; Kretschmer V
    Blood Coagul Fibrinolysis; 2011 Mar; 22(2):144-7. PubMed ID: 21178586
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Comparative analysis and classification of von Willebrand factor/factor VIII concentrates: impact on treatment of patients with von Willebrand disease.
    Budde U; Metzner HJ; Müller HG
    Semin Thromb Hemost; 2006 Sep; 32(6):626-35. PubMed ID: 16977573
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.